Opendata, web and dolomites

BiomStrip SIGNED

Over-The-Counter Test Strip for Early-Stage Cancer Screening

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BiomStrip project word cloud

Explore the words cloud of the BiomStrip project. It provides you a very rough idea of what is the project "BiomStrip" about.

highest    market    fastest    disruptive    preventive    transform    engineer    breakthrough    overheads    building    risk    dysbiosis    detection    platform    alleviating    invasive    license    entry    diagnosed    handled    difficult    diseases    capacity    breast    sensitive    selectively    flora    spread    vastly    fashion    ipr    subsequently    survival    tech    causing    screening    counter    minimised    types    explosive    model    biomarker    vital    therapeutical    effort    burdens    strategic    business    time    accurate    rate    carry    options    detect    commercialisation    workplan    stage    sme    offers    solution    partnership    companies    death    device    plan    disease    successfully    gut    empowering    pathophysiological    markets    biomstrip    costly    intensity    sums    strategies    scalability    gradually    trl6    effectiveness    introduces    granting    diagnostics    therapy    compliance    pregnancy    globally    indicator    sensitivity    onset    pioneering    covered    grown    patients    drastically    form    deaths    feasibility    point    cancer    ultimately    suffers    microbial    healthcare    bought    multinational    resource    validation    detecting    tests    histological    super    designed    once    diagnostic    spent    drops    keeping   

Project "BiomStrip" data sheet

The following table provides information about the project.

Coordinator
LOGODERM OKTATO ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG 

Organization address
address: GARDONYI GEZA UTCA 39
city: DEBRECEN
postcode: 4032
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Hungary [HU]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOGODERM OKTATO ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG HU (DEBRECEN) coordinator 50˙000.00

Map

 Project objective

Cancer is the second leading cause of death globally, causing 1 in 6 deaths. If cancer is diagnosed at early stage, it is highly likely to be treated successfully. Once it has grown and spread, therapy is vastly more difficult and costly, and survival rate drops rapidly. Screening is a vital healthcare element for early detection but suffers from burdens of cost, capacity, compliance, and detection sensitivity problems. BiomStrip introduces a pioneering screening solution that can carry out cancer screening in the fashion of the common pregnancy tests. Building on our recent breakthrough results in biomarker validation granting TRL6 stage, we have designed a diagnostic device that is low-cost, non-invasive, accurate, can be handled by consumer, and bought over-the counter. The diagnostic method is based on detecting dysbiosis of gut microbial flora, a highly sensitive indicator of pathophysiological processes able to selectively show disease onset at super-early stage, even before histological changes are observable. The method is ultimately able to detect most cancer types and even other diseases, making it a future platform technology. For highest scalability, fastest time-to-market, explosive growth, low resource-intensity, and minimised risk and overheads, we will license production and commercialisation to established multinational companies, keeping our focus as high-tech SME. Breast cancer will be our market entry point and other diseases will be covered subsequently form own resources. To engineer this Workplan, a feasibility study will assess entry use cases and their markets, analyse business model and partnership options, and evaluate IPR strategies in a Strategic Business Plan. The disruptive approach offers to transform cancer screening from top-down to bottom-up: empowering patients, gradually alleviating healthcare systems large effort and sums spent on preventive cancer diagnostics, and drastically improving therapeutical effectiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOMSTRIP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOMSTRIP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More